Estrogen Monotherapy for Testosterone Suppression in Gender Diverse Patients
October 2024
in “
Journal of the Endocrine Society
”
This study retrospectively reviewed estrogen monotherapy for testosterone suppression in gender diverse individuals assigned male at birth, specifically focusing on transfeminine patients. Out of 10 patients aged 19-81, 7 transfeminine patients achieved testosterone suppression with serum estradiol levels over 100 pg/mL, using either injectable or transdermal estrogen formulations. Injectable formulations were more common among those who achieved suppression. The study suggests that estrogen monotherapy could be effective without anti-androgens, though the small sample size is a limitation. Further research is needed to explore its potential for simplifying treatment protocols.